不可切除胰腺癌全身治疗试验强制测量共识(COMM-PACT)
Variations in the reporting of potentially confounding variables in studies investigating systemic treatments for unresectable pancreatic cancer pose challenges in drawing accurate comparisons between findings.…
要点
- COMM-PACT共识确定了不可切除胰腺癌试验中23项基线特征和12项预后特征为强制报告项目。
- 该共识旨在允许胰腺癌研究间结果的可比性,减少报告变异带来的比较困难。
核心结论
- COMM-PACT共识确定了不可切除胰腺癌未来试验中强制报告的23项基线特征和12项预后特征,以允许研究间结果的充分比较。
研究设计与样本
- 采用两轮改良Delphi专家共识,由23位胰腺癌领域国际领先肿瘤内科专家参与。
主要发现
- 识别出32项基线特征和26项预后特征。
- 经两轮共识后,23项基线特征和12项预后特征被指定为未来胰腺癌试验的强制项目。
关键数值与推荐
- 23项基线特征和12项预后特征被指定为未来不可切除胰腺癌试验的强制报告项目。
临床怎么用
- 未来不可切除胰腺癌全身治疗试验应报告COMM-PACT共识指定的23项基线特征和12项预后特征。
- 该共识有助于减少报告变异,促进胰腺癌研究间结果的充分比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Variations in the reporting of potentially confounding variables in studies investigating systemic treatments for unresectable pancreatic cancer pose challenges in drawing accurate comparisons between findings. In this Review, we establish the first international consensus on mandatory baseline and prognostic characteristics in future trials for the treatment of unresectable pancreatic cancer. We did a systematic literature search to find phase 3 trials investigating first-line systemic treatment for locally advanced or metastatic pancreatic cancer to identify baseline characteristics and prognostic variables. We created a structured overview showing the reporting frequencies of baseline characteristics and the prognostic relevance of identified variables. We used a modified Delphi panel of two rounds involving an international panel of 23 leading medical oncologists in the field of pancreatic cancer to develop a consensus on the various variables identified. In total, 39 randomised controlled trials that had data on 15 863 patients were included, of which 32 baseline characteristics and 26 prognostic characteristics were identified. After two consensus rounds, 23 baseline characteristics and 12 prognostic characteristics were designated as mandatory for future pancreatic cancer trials. The COnsensus statement on Mandatory Measurements in unresectable PAncreatic Cancer Trials (COMM-PACT) identifies a mandatory set of baseline and prognostic characteristics to allow adequate comparison of outcomes between pancreatic cancer studies.
引用
- Ter Veer E, van Rijssen LB, Besselink MG, et al. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol. 2018. PMID: 29508762. doi:10.1016/S1470-2045(18)30098-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。